Showing papers in "Value in Health in 2016"

TL;DR: In this paper, the authors present the ESTIMATE checklist, which includes a list of questions to consider when justifying the choice of analysis method, describing the analysis, and interpreting the results.

TL;DR: A Dutch tariff for the EQ-5D-5L is established on the basis of composite time trade-off (cTTO) to estimate the impact of health care interventions on quality of life, for example, in context of economic evaluations.

TL;DR: Estimating opportunity-cost-based cost-effectiveness thresholds for low-/middle-income countries can provide a useful input to inform resource allocation decisions and suggest that routinely used CETs have been too high.

TL;DR: This initial ISPOR MCDA task force report provides an introduction to MCDA and provides examples of its use in different kinds of decision making in health care (including benefit risk analysis, health technology assessment, resource allocation, portfolio decision analysis, shared patient clinician decision making and prioritizing patients' access to services).

TL;DR: This second task force report provides emerging good-practice guidance on the implementation of multiple criteria decision analysis to support health care decisions and provides an overview of the skills and resources required to implement MCDA.

TL;DR: A systematic review of recently published articles that reported costs of obesity and a meta-analysis found that the annual medical spending attributable to an obese individual was $1901 ($1239-$2582) in 2014 USD, accounting for $149.4 billion at the national level.

TL;DR: Persisting variability in stakeholder definitions of RWD may lead to disparities among different stakeholders when discussing RWD use in decision making.

TL;DR: The iDSI Reference Case is an aid to thought, not a substitute for it, and should not be followed slavishly without regard to context, culture, or history, and can be used as a framework for capacity building and technical assistance in LMICs.

TL;DR: On comparing the observed cTTO scores, it is found that the hybrid model was slightly superior to the simpler methods, including the TTO model.

TL;DR: In this paper, a literature review and stakeholder interviews were conducted to collect information on real-world data (RWD) policies for six European HTA agencies on RWD use in relative effectiveness assessments (REA) of drugs.

TL;DR: It is found that thresholds based on society's valuation of a QALY are generally larger than thresholds resulting from estimating the opportunity cost to the health care system, implying that some interventions with positive social net benefits, as informed by individuals' preferences, might not be an appropriate use of resources under fixed budget constraints.

TL;DR: This report aimed to provide a framework for researchers to plan the collection of health-utility data in clinical studies to provide high-quality HSU estimates for economic modeling.

TL;DR: Key concepts in patient preference assessment of particular importance for regulators and researchers are addressed in the MDIC Framework for patient centered benefit-risk assessment as well as the unique public-private collaboration that led its development.

TL;DR: In this paper, a focused literature review was conducted across the gray literature and articles published in English reporting insights on the EEG concept, and the identification of different "paradigms" was performed by simple inductive analysis of the documents' content.

TL;DR: As health care systems continue to evolve and establish patients as the primary stakeholder in their health care decision making, the pharmaceutical industry will need to be innovative to demonstrate the value of their products relative to the outcomes experienced by patients.

TL;DR: How preferences are currently being considered in the benefit-risk assessment context is described, and how different methods of preference elicitation are used to support decision making within the European context is shown.

TL;DR: In this article, the impact of complications on summary measures of health-related quality of life among people with type 2 diabetes was measured using EQ-5D-3L utility score.

TL;DR: Two significant studies are summarized that were developed in collaboration and consultation with CDER and CDRH and issued draft guidance in May and June 2015 on including patient-preference data in regulatory submissions.

TL;DR: Understanding drivers of biosimilar uptake becomes a critical issue to inform policy decision-makers and showed that incentive policies to enhance uptake remain an important driver of biosimilars penetration, while biosimilar price discounts have no impact.

TL;DR: It is shown that a side-splitting model can be viewed as a special case of design-by-treatment interaction model, and different parameterizations correspond to different design- by-treatment interactions.

TL;DR: In this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.

TL;DR: The estimates provided in this research may be useful for analysts attempting to model the impact of diabetes and diabetes-related comorbid conditions on utility.

TL;DR: This article presents the first conceptual modeling framework for public health economic evaluation, which could improve the quality of Public Health economic models, supporting efficient allocation of scarce resources.

TL;DR: Modest but significant improvements in patient-centered outcomes were observed after medication adherence interventions, and risk of bias analyses suggested links between study quality and SMDs.

TL;DR: There is a paucity of health economic evaluations conducted from the patient's perspective in the literature, and with the increasing focus on patient-centered outcomes in health policy research, more frequent use of the patients' perspective in economic studies should be advocated.

TL;DR: The findings suggest that the MGLS, as presently used, lacks consistency in an elderly population and may reflect causes as well as the extent of medication adherence.

TL;DR: Compared with PSA-only screening, the use of a PHI test can substantially reduce the number of negative biopsies and improve the cost-effectiveness of prostate cancer detection.

TL;DR: Important heterogeneity in policies on biosimilars was seen between (and even within) selected countries, which may partly explain variations in biosimilar uptake.